

## REFERENCES

- Barton, M., Hovey, E., & Reeve, T. (2009). Clinical practice guidelines for the management of adult gliomas: Astrocytomas and oligodendrogliomas. *Asia-Pacific Journal of Clinical Oncology* (Vol. 5). <https://doi.org/10.1111/j.1743-7563.2009.01253.x>
- Binabaj, M. M., Bahrami, A., ShahidSales, S., Joodi, M., Joudi Mashhad, M., Hassanian, S. M., ... Avan, A. (2017). The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. *Journal of Cellular Physiology*, 233(1), 378–386. <https://doi.org/10.1002/jcp.25896>
- Butowski, N. A., & Chang, S. M. (2006). Glial tumors: the current state of scientific knowledge. *Clinical Neurosurgery*, 53, 106–113.
- Cankovic, M., Nikiforova, M. N., Snuderl, M., Adesina, A. M., Lindeman, N., Wen, P. Y., & Lee, E. Q. (2013). The Role of MGMT Testing in Clinical Practice. *The Journal of Molecular Diagnostics*, 15(5), 539–555. <https://doi.org/10.1016/j.jmoldx.2013.05.011>
- Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017). Glioma Subclassifications and Their Clinical Significance. *Neurotherapeutics*, 14(2), 284–297. <https://doi.org/10.1007/s13311-017-0519-x>
- Claus, E. B., Walsh, K. M., Wiencke, J. K., Molinaro, A. M., Wiemels, J. L., Schildkraut, J. M., ... Wrensch, M. (2015). Survival and low-grade glioma: the emergence of genetic information. *Neurosurgical Focus*, 38(1), E6. <https://doi.org/10.3171/2014.10.focus12367>
- Colman, H., & Aldape, K. (2010). Molecular Pathogenesis. In *Primary Central Nervous System Tumors* (pp. 27–44). Humana Press. [https://doi.org/10.1007/978-1-60761-166-0\\_2](https://doi.org/10.1007/978-1-60761-166-0_2)
- Diwanji, T. P., Engelman, A., Snider, J. W., & Mohindra, P. (2017). Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. *Adolescent Health, Medicine and Therapeutics*, Volume 8, 99–113. <https://doi.org/10.2147/ahmt.s53391>
- Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., ... Jenkins, R. B. (2015). Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *New England Journal of Medicine*, 372(26), 2499–2508. <https://doi.org/10.1056/nejmoa1407279>
- Everhard, S., Kaloshi, G., Crinière, E., Benouaich-Amiel, A., Lejeune, J., Marie, Y., ... Thiller, J. (2006). MGMT methylation: A marker of response to

temozolomide in low-grade gliomas. *Annals of Neurology*, 60(6), 740–743. <https://doi.org/10.1002/ana.21044>

Fabi, A., Metro, G., Russillo, M., Vidiri, A., Carapella, C. M., Maschio, ... Pace, A. (2009). Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. *BMC Cancer*, 9(1), 1–8. <https://doi.org/10.1186/1471-2407-9-101>

Field, A. E., Robertson, N. A., Wang, T., Havas, A., Ideker, T., & Adams, P. D. (2018). DNA Methylation Clocks in Aging: Categories, Causes, and Consequences. *Molecular Cell*, 71(6), 882–895. <https://doi.org/10.1016/j.molcel.2018.08.008>

Florian, I. S., Ungureanu, G., & Berce, C. (2013). Risk factors for gliomas. An extensive review. *Romanian Neurosurgery*, 20(1), 5–21. <https://doi.org/10.2478/v10282-012-0016-z>

Gehring, K., Sitskoorn, M. M., Gundy, C. M., Sikkes, S. A. M., Klein, M., Postma, T. J., ... Aaronson, N. K. (2009). Cognitive Rehabilitation in Patients With Gliomas: A Randomized, Controlled Trial. *Journal of Clinical Oncology*, 27(22), 3712–3722. doi:10.1200/jco.2008.20.5765

Gladson, C. L., Prayson, R. A., & Liu, W. M. (2010). The Pathobiology of Glioma Tumors. *Annual Review of Pathology: Mechanisms of Disease*, 5(1), 33–50. <https://doi.org/10.1146/annurev-pathol-121808-102109>

Global Cancer Observatory. (2018). Population Fact Sheets Indonesia.

Greenberg, M. (2016). *Handbook of neurosurgery*. New York: Thieme

Hanif, F., Muzaffar, K., Perveen, K., Malhi, S., & Simjee, S. (2017). Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. *Asian Pacific Journal of Cancer Prevention*, 18(1). <https://doi.org/10.22034/APJCP.2017.18.1.3>

Hatch, E. E., Linet, M. S., Zhang, J., Fine, H. A., Shapiro, W. R., Selker, R. G., ... Inskip, P. D. (2004). Reproductive and hormonal factors and risk of brain tumors in adult females. *International Journal of Cancer*, 114(5), 797–805. <https://doi.org/10.1002/ijc.20776>

Håvik, A. B., Brandal, P., Honne, H., Dahlback, H. S. S., Scheie, D., Hektoen, M., ... Lind, G. E. (2012). MGMT promoter methylation in gliomas—assessment by pyrosequencing and quantitative methylation-specific PCR. *Journal of Translational Medicine*, 10(1), 1–13. <https://doi.org/10.1186/1479-5876-10-36>

- Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., ... Stupp, R. (2005). MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. *New England Journal of Medicine*, 352(10), 997–1003. <https://doi.org/10.1056/nejmoa043331>
- Ho, V. K. Y., Reijneveld, J. C., Enting, R. H., Bienfait, H. P., Robe, P., Baumert, B. G., & Visser, O. (2014). Changing incidence and improved survival of gliomas. *European Journal of Cancer*, 50(13), 2309–2318. <https://doi.org/10.1016/j.ejca.2014.05.019>
- Huang, K., Whelan, E. A., Ruder, A. M., Ward, E. M., Deddens, J. A., Davis-King, K. E., ... Rosenman, K. D. (2004). Reproductive factors and risk of glioma in women. *Cancer Epidemiology Biomarkers and Prevention*, 13(10), 1583–1588.
- Jäkel, S., & Dimou, L. (2017). Glial Cells and Their Function in the Adult Brain: A Journey through the History of Their Ablation. *Frontiers in Cellular Neuroscience*, 11(February), 1–17. <https://doi.org/10.3389/fncel.2017.00024>
- Karsy, M., Neil, J. A., Guan, J., Mahan, M. A., Colman, H., & Jensen, R. L. (2015). A practical review of prognostic correlations of molecular biomarkers in glioblastoma. *Journal of Neuro-Oncology*, 38(March), 1–8. <https://doi.org/10.3171/2015.1.FOCUS14755>
- Kementrian Kesehatan Republik Indonesia. (2017). *Pedoman Nasional Penanganan Kedokteran Tumor Otak*. Jakarta.
- Khazatsin, H. A., Anindita, T., Soetrisno, E., & Prihartono, J. (2014). Gambaran Status Metilasi Gen Promoter Methylguanine-Deoksiribonucleic Acid Methyltransferase Pada Astrositoma Dan Faktor-Faktor Yang Mempengaruhinya. *Program Pendidikan Dokter Spesialis Neurologi*.
- Kim, Y. Z., Song, Y. J., Kim, K. U., & Kim, D. C. (2011). MGMT gene promoter methylation analysis by pyrosequencing of brain tumour. *Korean Journal of Pathology*, 45(5), 455–462. <https://doi.org/10.4132/KoreanJPathol.2011.45.5.455>
- Kumar, V., Abbas, A., Aster, J. & Robbins, S. (2013). *Robbins basic pathology*. Philadelphia, PA: Elsevier/Saunders.
- Kumar, V. M. M., Abbas, A. K. M., & Aster, J. C. M. P. (2015). *Robbins & Cotran Pathologic Basis of Disease, 9th Edition*.
- Larjavaara, S., Mäntylä, R., Salminen, T., Haapasalo, H., Raitanen, J., Jääskeläinen, J., & Auvinen, A. (2007). Incidence of gliomas by anatomic

location. Neuro-Oncology, 9(3), 319–325.  
<https://doi.org/10.1215/15228517-2007-016>

Liao, P., Ostrom, Q. T., Stetson, L., & Barnholtz-Sloan, J. S. (2018). Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence. *Neuro-Oncology*, 20(7), 942–953. <https://doi.org/10.1093/neuonc/noy003>

Lötsch, D., Ghanim, B., Laaber, M., Wurm, G., Weis, S., Lenz, S., ... Spiegl-Kreinecker, S. (2013). Prognostic significance of telomerase-associated parameters in glioblastoma: Effect of patient age. *Neuro-Oncology*, 15(4), 423–432. <https://doi.org/10.1093/neuonc/nos329>

Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., ... Ellison, D. W. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica*, 131(6), 803–820. <https://doi.org/10.1007/s00401-016-1545-1>

Madiyono, B., Moeslichan, S., Sastroasmoro, S., Budiman, I., & Purwanto, S. H. (2014). Perkiraan besar sampel. In S. Sastroasmoro & S. Ismael (Eds.), *Dasar-dasar Metodologi Penelitian Klinis Edisi-5* (5th ed., pp. 352–387). Jakarta: Sagung Seto.

Maile, E. J., Barnes, I., Finlayson, A. E., Sayeed, S., & Ali, R. (2016). Nervous system and intracranial tumour incidence by ethnicity in England, 2001–2007: A descriptive epidemiological study. *PLoS ONE*, 11(5), 2001–2007. <https://doi.org/10.1371/journal.pone.0154347>

Marttila, S., Kananen, L., Häyrynen, S., Jylhävä, J., Nevalainen, T., Hervonen, A., ... Hurme, M. (2015). Ageing-associated changes in the human DNA methylome: genomic locations and effects on gene expression. *BMC Genomics*, 16(1). <https://doi.org/10.1186/s12864-015-1381-z>

Mescher, A. (2013). *Junqueira's basic histology: text and atlas*. New York: McGraw Hill Medical.

Nakamura, M., Watanabe, T., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2001). Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. *Carcinogenesis*, 22(10), 1715–1719.

Ohgaki, H., & Kleihues, P. (2007). Genetic Pathways to Primary and Secondary Glioblastoma. *The American Journal of Pathology*, 170(5), 1445–1453. <https://doi.org/10.2353/ajpath.2007.070011>

- Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., ... Barnholtz-Sloan, J. S. (2014). The epidemiology of glioma in adults: a “state of the science” review. *Neuro-Oncology*, 16(7), 896–913. <https://doi.org/10.1093/neuonc/nou087>
- Perez-Larraya, G & Delattre, J.-Y. (2014). Management of Elderly Patients With Gliomas. *The Oncologist*, 19(12), 1258–1267. <https://doi.org/10.1634/theoncologist.2014-0170>
- Paugh, B. S., Qu, C., Jones, C., Liu, Z., Adamowicz-Brice, M., Zhang, J., ... Baker, S. J. (2010). Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease. *Journal of Clinical Oncology*, 28(18), 3061–3068. <https://doi.org/10.1200/jco.2009.26.7252>
- Piñeros, M., Sierra, M. S., Izarzugaza, M. I., & Forman, D. (2016). Descriptive epidemiology of brain and central nervous system cancers in Central and South America. *Cancer Epidemiology*, 44, S141–S149. <https://doi.org/10.1016/j.canep.2016.04.007>
- Reifenberger, G., Hentschel, O., Felsberg, B., Schackert, G., Simon, M., Schnell, J., Westphal, M., Wick, W., ... Pietsch, T. (2011). Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. *International Journal of Cancer*, 131(6), 1342–1350. <https://doi.org/10.1002/ijc.27385>
- Rivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Cruz, C., Sulman, E. P., ... Aldape, K. D. (2009). MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. *Neuro-Oncology*, 12(2), 116–121. <https://doi.org/10.1093/neuonc/nop020>
- Sharma, S., Salehi, F., Scheithauer, B. W., Rotondo, F., Syro, L. V., & Kovacs, K. (2009). Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. *Anticancer Research*, 29(10), 3759–3768.
- Shen, D., Liu, T., Lin, Q., Lu, X., Wang, Q., Lin, F., & Mao, W. (2014). MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study. *PLoS ONE*, 9(9), e107558. <https://doi.org/10.1371/journal.pone.0107558>
- Silber, J. R., Bobola, M. S., Ghatan, S., Blank, A., Kolstoe, D. D., & Berger, M. S. (1998). O6-Methylguanine-DNA Methyltransferase Activity in Adult Gliomas: Relation to Patient and Tumor Characteristics. *Cancer Research*, 58(5), 1068 LP-1073.

- Sun, T., Plutynski, A., Ward, S., & Rubin, J. B. (2015). An integrative view on sex differences in brain tumors. *Cellular and Molecular Life Sciences*, 72(17), 3323–3342. <https://doi.org/10.1007/s00018-015-1930-2>
- Szopa, W., Burley, T. A., Kramer-Marek, G., & Kaspera, W. (2017). Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. *BioMed Research International*, 2017, 1–13. <https://doi.org/10.1155/2017/8013575>
- Villani, V., Casini, B., Pace, A., Prosperini, L., Carapella, C. M., Vidiri, A., ... Carosi, M. (2015). The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma. *Disease Markers*, 2015, 1–6. <https://doi.org/10.1155/2015/604719>
- Vlassenbroeck, I., Califice, S., Diserens, A. C., Migliavacca, E., Straub, J., Di Stefano, I., ... Hegi, M. E. (2008). Validation of real-time methylation-specific PCR to determine O 6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. *Journal of Molecular Diagnostics*, 10(4), 332–337. <https://doi.org/10.2353/jmoldx.2008.070169>
- Walsh, K. M., & Wrensch, M. R. (2018). *118 Epidemiology of Brain Tumors. Youmans and Winn Neurological Surgery, 4-Volume Set* (Seventh Edition). Elsevier Inc.
- Weller, M., Tabatabai, G., Kastner, B., Felsberg, J., Steinbach, J. P., ... Wick, A. (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. *Clinical Cancer Research*, 21(9), 2057–2064. <https://doi.org/10.1158/1078-0432.CCR-14-2737>
- Wigertz, A., Lönn, S., Mathiesen, T., Ahlbom, A., Hall, P., & Feychting, M. (2006). Risk of Brain Tumors Associated with Exposure to Exogenous Female Sex Hormones. *American Journal of Epidemiology*, 164(7), 629–636. <https://doi.org/10.1093/aje/kwj254>
- Yoshioka, M., Hirono, S., Matsutani, T., Takiguchi, M., Iwadate, Y., Hara, A., & Hiwasa, T. (2018). Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma. *Oncotarget*, 9(45), 27728–27735. <https://doi.org/10.18632/oncotarget.25543>
- Yin, A. A., Zhang, L. H., Cheng, J. X., Dong, Y., Liu, B. L., Han, N., & Zhang, X. (2014). The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: A meta-analysis. *PLoS ONE*, 9(1). <https://doi.org/10.1371/journal.pone.0085102>